

Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, October 15, 2025, 9 a.m. to 4 p.m.

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Peter Barkett, Committee Chair
	Insomnia <ul style="list-style-type: none"> Stakeholder input* Motion 	Jana Schellinger, MLIS; DERP
	MS <ul style="list-style-type: none"> Stakeholder input* Motion 	Courtney Cooper, MPH; DERP
	P&T Committee Adjourns Lunch (10 min)	Peter Barkett, Committee Chair All
	Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Peter Barkett, Committee Chair
	Apple Health Policy: 39.38.00 - Antihyperlipidemics : Adenosine Triphosphate- Citrate Lyase Inhibitors <ul style="list-style-type: none"> Stakeholder input* Motion 	Marissa Tabile, HCA
	Apple Health Policy: 40.90.00 - Cardiovascular Agents : Vasoactive Soluble Guanylate Cyclase Stimulators <ul style="list-style-type: none"> Stakeholder input* Motion 	Ryan Taketomo, HCA
	Antihyperlipidemics <ul style="list-style-type: none"> Adenosine Triphosphate-Citrate Lyase Inhibitors Angiopoietin-Like Protein Inhibitors Microsomal Triglyceride Transfer Protein (MTP) Inhibitor PCSK-9 Inhibitors <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions
 please call Nonye Connor at 360-725-2044.

	Drug Utilization Review (DUR) Lunch (30 min)	All
	Antivirals <ul style="list-style-type: none"> Influenza Agents <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime
	Cardiovascular Agents <ul style="list-style-type: none"> Transthyretin Stabilizers <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime
	Genitourinary Agents <ul style="list-style-type: none"> Overactive Bladder Agents <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime
	Hematological Agents <ul style="list-style-type: none"> Hereditary Angioedema Agents <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime
	Multiple Sclerosis Agents : <ul style="list-style-type: none"> <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime
	Ophthalmic Agents <ul style="list-style-type: none"> Cholinergic Agonists Complement Inhibitors <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime
	Oncology Agents <ul style="list-style-type: none"> Antiandrogens HIF-2-Alpha Inhibitors KRAS Inhibitors <ul style="list-style-type: none"> Stakeholder input* Motion 	Nina Huynh, Prime
	Break (10 min)	All
	Allergy <ul style="list-style-type: none"> Antihistamines – Injectable Misc – Nasal 	Marissa Tabile, HCA Nina Huynh, Prime

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<p>Antidepressants</p> <ul style="list-style-type: none"> GABA Receptor Modulator - Neuroactive Steroid <p>Antidiabetics</p> <ul style="list-style-type: none"> Cellular Therapy <p>Antifungals</p> <ul style="list-style-type: none"> Topical <p>Antivirals</p> <ul style="list-style-type: none"> Smallpox Agents <p>Atopic Dermatitis Agents</p> <ul style="list-style-type: none"> Immunosuppressive Agents - Topical Combinations <p>Cardiovascular Agents</p> <ul style="list-style-type: none"> Misc Sinus Node Inhibitors Vasoactive Soluble Guanylate Cylcase Stimulators (SGC) <p>Endocrine and Metabolic Agents</p> <ul style="list-style-type: none"> Fabry Disease Agents – Injectable Fabry Disease Agents – Oral Fatty Acid Metabolism Agents GAA Deficiency Agents Growth Hormone Releasing Hormones (GHRH) Growth Hormones Lysosomal Acid Lipase Deficiency Agents Mucopolysaccharidosis Agents NH3 Inhibitors Parathyroid Hormones Pituitary Suppressants Urea Cycle Disorder Agents – Oral Vasopressin Receptor Antagonists - Oral <p>Gastrointestinal Agents</p> <ul style="list-style-type: none"> Inflammatory Bowel Agents Irritable Bowel Syndrome (IBS) Agents / GI Motility Phosphate Binder Agents Short Bowel Syndrome <p>Genitourinary Agents</p> <ul style="list-style-type: none"> Prostatic Hypertrophy Agents <p>Glaucoma Agents</p> <ul style="list-style-type: none"> Adrenergic Agents Adrenergic Agents Combinations Beta – Blockers Beta - Blockers Combinations Carbonic Anhydrase Inhibitors Kinase Inhibitors Miotics Prostaglandins <p>Hematological Agents</p> <ul style="list-style-type: none"> Aminolevulinate Synthase 1-Directed siRNA Pyruvate Kinase Activators <p>Hematopoeitic Agents</p> <ul style="list-style-type: none"> Autologous Cellular Gene Therapy CXCR4 Receptor Antagonists 	
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> • Stem Cell Mobilizers • Thrombopoiesis (TPO) Stimulating Proteins <p>Miscellaneous Therapeutic Classes</p> <ul style="list-style-type: none"> • Allogeneic Thymus Tissue • Phosphoinositide 3-Kinase Agents • Potassium Removing Agents • Progeria Treatment Agents <p>Movement Disorder Agents :</p> <ul style="list-style-type: none"> • <p>Neuromuscular Agents</p> <ul style="list-style-type: none"> • Freidrichs Ataxia Agents • Rett Syndrome Agents • Systemic Lupus Erythematosus Agents <p>Oncology Agents</p> <ul style="list-style-type: none"> • Allogenic Cellular Immunotherapy • Androgen Biosynthesis Inhibitors – Oral • Antiandrogens – Oral • FGFR Kinase Inhibitors – Oral • Gamma Secretase Inhibitors • Gonadotropin-Releasing Hormone (GNRH) Receptor Antagonists - Oral • Hedgehog Pathway Inhibitors – Oral • Interferons • LHRH Analogs - Injectable • Methyltransferase Inhibitors – Oral • MTOR Kinase Inhibitors – Oral • Multikinase Inhibitors – Oral • Ornithine Decarboxylase Inhibitors • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors – Oral • Retinoids – Oral • Topoisomerase Inhibitors – Oral • Urinary Tract Protective Rescue Agents - Oral <p>Ophthalmic Agents</p> <ul style="list-style-type: none"> • Ectoparasitocides • Immunomodulators • Nerve Growth Factors <p>Pulmonary Hypertension Agents</p> <ul style="list-style-type: none"> • Activin Signaling Inhibitor • Combinations <p>Respiratory Agents</p> <ul style="list-style-type: none"> • Pulmonary Fibrosing Agents <p>Smoking Deterrents</p> <ul style="list-style-type: none"> • Misc – Other <p>Substance Use Disorder</p> <ul style="list-style-type: none"> • Agents for Opioid Withdrawal • Opioid Antagonists • Opioid Partial Agonists – Subcutaneous • Opioid Partial Agonists – Transmucosal <p>Vasopressors</p> <ul style="list-style-type: none"> • Misc – Oral <p>Vitamins</p>	
--	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> Vitamin D / Vitamin D Analogs – Oral <p>All classes in this section:</p> <ul style="list-style-type: none"> Stakeholder input* Motion 	
3:10 p.m.	Drug Utilization Review (DUR) Board Adjourns	Peter Barkett, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.



** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.